AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19424036
Drug: Standard-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclosporine A (CsA; 150-300 ng/mL for 3 months then 100-200 ng/mL)
Trial: 19424036
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine A (CsA; 50-100 ng/mL)
Trial: 19424036
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (Tac; 3-7 ng/mL)
Trial: 19424036
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus (SRL; 4-8 ng/mL)
Trial: 11817530
Drug: Mannitol 4
RxNorm normalized name: mannitol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 4 g/l
Trial: 11817530
Drug: Mannitol 8
RxNorm normalized name: MITOMYCIN 40MG/MANNITOL 80MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 8 g/l
Trial: 357456
Drug: Diphenhydramine (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (12.5, 25, or 50 mg)
Trial: 357456
Drug: Methapyrilene (36,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methapyrilene (36, 72, or 144 mg)
Trial: 7058839
Drug: Inhaled isoproterenol
RxNorm normalized name: isoproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoproterenol alone
Trial: 7058839
Drug: Isoproterenol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol plus intravenous aminophylline
Trial: 7058839
Drug: Isoproterenol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol plus a single oral dose of an elixir of theophylline
Trial: 7058839
Drug: Injectable sympathomimetic
RxNorm normalized name: Sympathomimetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable sympathomimetic agent (given if treatment beyond 60 minutes was required)
Trial: 25200037
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg orally 1 hour prior to induction of anesthesia
Trial: 20923841
Drug: GP sequential
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP sequential testing
Trial: 12044531
Drug: LAM/IFN combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM/IFN combination therapy (IFN at 5MU t.i.w. + LAM at 100mg/day)
Trial: 12044531
Drug: LAM monotherapy
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM monotherapy (LAM at 100mg/day)
Trial: 10527090
Drug: Isokinetic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isokinetic exercise of the quadriceps muscle three times weekly over 8 weeks
Trial: 8821072
Drug: Dopamine-agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine-agonists
Trial: 2626285
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg for children younger than 12 years and 12 mg for adults every 12 hours for 3 days) in addition to standard antibacterial chemotherapy (ampicillin and chloramphenicol)
Trial: 2626285
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibacterial chemotherapy alone)
Trial: 1105112
Drug: Gentamicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (80 mg intramuscular injection at the time of anaesthetic premedication)
Trial: 29319061
Drug: Xylitol gum
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol gum plus oral health education
Trial: 19605879
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education alone
Trial: 16334720
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Liuwei Dihuang Wan (Bolus of the Six Drugs Including Rehmanniae)
Trial: 9523308
Drug: Risedronate solution
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate solution 40 mg in 30 mL of water administered directly into the stomach, second part of the duodenum, or terminal ileum over 1 minute (study A)
Trial: 9523308
Drug: Risedronate solution
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate solution 40 mg in 30 mL of water administered directly into the second part of the duodenum over 1 minute and over 1 hour (study B)
Trial: 8595642
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 to 40 mg twice daily
Trial: 785178
Drug: Sisomicin 75
RxNorm normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisomicin 75 or 100mg (1.4 mg/kg) single intramuscular injection
Trial: 785178
Drug: Sisomicin 50
RxNorm normalized name: sisomicin 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisomicin 50 or 75mg (1.9 or 2.1 mg/kg) b.i.d.
Trial: 11246243
Drug: Low-volume ventriculography
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume ventriculography (15 mL/sec for 1 sec)
Trial: 11246243
Drug: Standard-volume ventriculography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-volume ventriculography (15 mL/sec for 3 sec)
Trial: 27450231
Drug: Greenselect Phytosome®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greenselect Phytosome® (150 mg/dose) and piperine (15 mg/dose)
Trial: 25368724
Drug: IvIg (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IvIg (0.4 g/kg/day for 5 days)
Trial: 23469601
Drug: Qiyao Xiaoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiyao Xiaoke Capsule (QXC), 0.4 g/pill, 6 pills each time, three times a day.
Trial: 23469601
Drug: Qiyao Xiaoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiyao Xiaoke Capsule (QXC)
Trial: 30278110
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L PEGA with PLD
Trial: 30278110
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L PEGA
Trial: 26245675
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Trastuzumab or Lapatinib
Trial: 23354353
Drug: Phospholipid-liposome solution
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid-liposome solution (Blepha Cura)
Trial: 21285986
Drug: Docetaxel (D)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (D) 30 mg/m² i.v. and Epirubicin (EPI) 30 mg/m² i.v. every week (D/EPI arm)
Trial: 21285986
Drug: Docetaxel (D)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (D) 70 mg/m² i.v. every 3 weeks and Prednisone (P) 5 mg twice daily (D/P arm)
Trial: 12851532
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin bolus
Trial: 12851532
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous heparin bolus
Trial: 8792695
Drug: Ranitidine HCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine HCI 150 mg twice daily
Trial: 8792695
Drug: Ranitidine HCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine HCI 150 mg twice daily plus metoclopramide HCI 10 mg four times daily
Trial: 8792695
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (ranitidine + metoclopramide)
Trial: 6332178
Drug: High-dose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusion methotrexate (1,500 mg/m2) with leucovorin
Trial: 6332178
Drug: Standard-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose methotrexate (40 mg/m2) without leucovorin
Trial: 6332178
Drug: High-dose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusion methotrexate
Trial: 6332178
Drug: Standard-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose methotrexate
Trial: 6332178
Drug: High-dose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose infusion methotrexate and Standard-dose methotrexate
Trial: 31447547
Drug: Dextromethorphan (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (90 mg/day)
Trial: 11867965
Drug: Clobetasol lotion
RxNorm normalized name: clobetasol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol lotion under hydrocolloid occlusion once weekly
Trial: 11867965
Drug: Clobetasol ointment
RxNorm normalized name: clobetasol Topical Ointment
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol ointment twice daily
Trial: 10573105
Drug: MPEMi combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPEMi combination (Methotrexate, Cisplatin, Etoposide, Mitomycin)
Trial: 10573105
Drug: MPEpiE combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPEpiE combination (Methotrexate, Cisplatin, Epirubicin, Etoposide)
Trial: 10573105
Drug: MPEpiV combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPEpiV combination (Methotrexate, Cisplatin, Epirubicin, Vincristine)
Trial: 26252485
Drug: NNC0109‐0012 (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0109‐0012 (0.01, 0.05, 0.2, 0.6, 1.5, or 3.0 mg/kg single doses; 0.05, 0.2, 0.5, 1.0, or 2.0 mg/kg multiple doses every other week for 7 weeks; 2.0 mg/kg weekly doses for 7 weeks in expansion phase)
Trial: 23723381
Drug: Proanthocyanidins (PA)
RxNorm normalized name: grape seed proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proanthocyanidins (PA) treatment
Trial: 18256415
Drug: Oral miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral miltefosine (2.5 mg/kg/d for 28 days)
Trial: 18256415
Drug: Intramuscular antimony
RxNorm normalized name: antimony
DrugBank: Antimony (DB13110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular antimony (20 mg/kg/d for 20 days)
Trial: 16612915
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (GTN) ointment, 0.2 percent, applied twice daily.
Trial: 16612915
Drug: Oral nifedipine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nifedipine, 20 mg twice daily, retard formulation.
Trial: 15322870
Drug: General recommendation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General recommendation for antimicrobial therapy
Trial: 9111852
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of individual out-patient and family treatment
Trial: 9111852
Drug: Individual out-patient
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual out-patient treatment
Trial: 31407484
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg before induction of anaesthesia, followed by 40 mg every 12 hours for 48 hours post-operation.
Trial: 31407484
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered 30 minutes before induction of anaesthesia, followed by placebo every 12 hours for 48 hours post-operation.
Trial: 28793834
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) with good therapist fidelity
Trial: 28793834
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) with below average therapist fidelity
Trial: 20140437
Drug: Tolterodine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 8 mg
Trial: 27948084
Drug: Tropisetron plus
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron plus dexamethasone (5 mg IV + 10 mg oral on days 1-5)
Trial: 27948084
Drug: Generic ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic ondansetron plus dexamethasone (24 mg IV + 10 mg oral on days 1-5)
Trial: 9213829
Drug: Heparansulphate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparansulphate 100 mg t.i.d.
Trial: 8448092
Drug: Obturator nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obturator nerve block using 5 mL of 2.0% lidocaine followed by two or three prognostic blocks using 5 mL of 0.5% bupivacaine and 1:200,000 epinephrine, and final block with 5 mL of 6.0% phenol in glycerin
Trial: 2876772
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (C. parvum) administered intrapleurally and intravenously (7 mg injected into the pleural space and 7 mg intravenously once between days 6 and 12 postoperatively, followed by 7 mg intravenously every 3rd month during the 1st year)
Trial: 2876772
Drug: Placebo (intrapleural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intrapleural administration of 35 cc of saline)
Trial: 30661702
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50000 IU weekly for 9 weeks)
Trial: 29282609
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum (5 × 10^7 cfu g−1)
Trial: 29282609
Drug: Lactobacillus bulgaricus
RxNorm normalized name: Lactobacillus bulgaricus
DrugBank: Lactobacillus delbrueckii bulgaricus (DB16540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus bulgaricus (5 × 10^7 cfu g−1)
Trial: 29282609
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei (5 × 10^7 cfu g−1)
Trial: 25378426
Drug: TMSsyn group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMSsyn group (synchronous picture-naming training with contralesional 1 Hz-rTMS for 10 daily sessions)
Trial: 25378426
Drug: TMSsham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMSsham group (concurrent naming task with sham 1 Hz-rTMS)
Trial: 15321258
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg diamorphine
Trial: 8476582
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg once daily for 7-14 days
Trial: 8476582
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg twice daily for 7-14 days
Trial: 23221579
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHA and 300 mg EPA supplementation for 6 months
Trial: 23221579
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL olive oil/d for 6 months (Control)
Trial: 21722960
Drug: Cyanocobalamin formulated
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin formulated with 100-mg SNAC (5 mg dose)
Trial: 21722960
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available 5-mg cyanocobalamin tablet
Trial: 21722960
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available 1-mg cyanocobalamin IV
Trial: 19303160
Drug: PI-88 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-88 (160 mg/day)
Trial: 19303160
Drug: PI-88 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-88 (250 mg/day)
Trial: 17040264
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate ointment 1%
Trial: 10931801
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose on day 1, followed by 75 mg/d) plus aspirin (325 mg/d)
Trial: 10931801
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d) plus aspirin (325 mg/d)
Trial: 10931801
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg BID) plus aspirin (325 mg/d)
Trial: 10931801
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Clopidogrel and Ticlopidine)
Trial: 7963711
Drug: sCD4‐PE40, 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD4‐PE40, 1, 5, 10, or 15 micrograms/kg by intravenous bolus once a month for 2 months, then weekly for 6 weeks.
Trial: 7963711
Drug: sCD4‐PE40, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD4‐PE40, 10 micrograms/kg (maximally tolerated dose).
Trial: 30396343
Drug: Moxibustion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion therapy with educational video program
Trial: 28205278
Drug: 1.25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 μg ramosetron
Trial: 28205278
Drug: 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg ramosetron
Trial: 28205278
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg ramosetron
Trial: 18204339
Drug: Pindolol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 7.5 mg/d
Trial: 8126146
Drug: Nal-Glu +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal-Glu + T 50 mg
Trial: 8126146
Drug: Nal-Glu +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal-Glu + T 100 mg
Trial: 8126146
Drug: Nal-Glu +
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal-Glu + T + Teslac 250 mg
Trial: 2577498
Drug: High-dose ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ranitidine (300 mg q.d.s.)
Trial: 2577498
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose ranitidine (300 mg nocte)
Trial: 2577498
Drug: Standard ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ranitidine therapy
Trial: 175669
Drug: Split-course radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-course radiation therapy
Trial: 175669
Drug: Continuous radiation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous radiation therapy
Trial: 27771761
Drug: Coping skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping skills training for junior gynecologists (12 weekly sessions over 3 months)
Trial: 19382463
Drug: Tanreqing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing Injection (20 mL) with 5% G/NS (500 mL) once a day for two weeks
Trial: 19382463
Drug: Yanhuning injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yanhuning injection (0.4 g) with 5% G/NS (500 mL) once a day for two weeks
Trial: 11952025
Drug: Enteric-coated fluoxetine
RxNorm normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated fluoxetine 90 mg on both days (LPWDx2)
Trial: 11952025
Drug: Placebo 14
RxNorm normalized name: Ascorbic Acid/Calcium Ascorbate/Calcium Threonate/Cyanocobalamin/Folic Acid/Iron/Succinic Acid;Placebo 140 MG-60 MG-0.8 MG-0.01 MG-1 MG-151 MG-150 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 14 days before menses and enteric-coated fluoxetine 90 mg 7 days before menses (LPWDx1)
Trial: 1771220
Drug: Glucose 0
RxNorm normalized name: glucose 0.4 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 0 g (Control)
Trial: 1771220
Drug: Glucose 30
RxNorm normalized name: glucose 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 30 g
Trial: 1771220
Drug: Glucose 100
RxNorm normalized name: glucose 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 100 g
Trial: 6941444
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g (single oral dose, pre-operatively)